| Enovis Corporation (ENOV) Q1 2025 Earnings Call Transcript |
Enovis Corporation (NYSE:ENOV ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matthew Trerotola - Chair and Chief Executive Officer Ben Berry - Chief Financial Officer Conference Call Participants Vik Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robert Marcus - JPMorgan Dane Reinhardt - Baird Danielle Antalffy - UBS Russell Yuen - William Blair Young Li - Jefferies Operator Hello, everyone, and welcome to the Enovis Corporation Q1 2025 Results Call. My name is Ezra, and I will be your coordinator today. |
seekingalpha.com |
2025-05-11 05:46:31 |
Czytaj oryginał (ang.) |
| Enovis (ENOV) Q1 Earnings and Revenues Surpass Estimates |
Enovis (ENOV) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.50 per share a year ago. |
zacks.com |
2025-05-08 12:30:41 |
Czytaj oryginał (ang.) |
| Enovis Announces First Quarter 2025 Results |
Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12 th , 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. |
globenewswire.com |
2025-05-08 10:00:00 |
Czytaj oryginał (ang.) |
| Enovis to Host First Quarter 2025 Results Conference Call on May 8th |
Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. |
globenewswire.com |
2025-04-17 11:00:00 |
Czytaj oryginał (ang.) |
| Enovis Announces Appointment of Damien McDonald as Chief Executive Officer |
WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million. |
globenewswire.com |
2025-04-02 10:30:00 |
Czytaj oryginał (ang.) |
| Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 |
WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year's American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30. |
globenewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Enovis to Participate in Upcoming Investor Conferences |
Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: |
globenewswire.com |
2025-03-05 18:05:00 |
Czytaj oryginał (ang.) |
| Enovis Continues To Languish Despite Decent Financial Results |
Enovis shares have continued to languish despite on-target financial performance, with Q4'24 results meeting expectations and featuring double-digit growth in its Reconstructive business. Enovis' Recon business outperformed its larger rivals in Q4, with double-digit growth in global hips and knees and double-digit growth in U.S. knees as well. Uncertainty from an unexpected CEO transition and potential 2025 tariffs only add to market hesitation. |
seekingalpha.com |
2025-02-28 10:23:40 |
Czytaj oryginał (ang.) |
| Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript |
Enovis Corporation (NYSE:ENOV ) Q4 2024 Results Conference Call February 26, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Jeff Johnson - Baird Brandon Vazquez - William Blair Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canaccord Jason Wittes - ROTH Operator Good day, and welcome to the Enovis Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2025-02-26 14:53:03 |
Czytaj oryginał (ang.) |
| Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates |
Enovis (ENOV) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago. |
zacks.com |
2025-02-26 10:16:30 |
Czytaj oryginał (ang.) |
| Enovis Announces Fourth Quarter and Full Year 2024 Results |
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. |
globenewswire.com |
2025-02-26 08:01:00 |
Czytaj oryginał (ang.) |
| Enovis Announces Planned CEO Succession Process |
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO. As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company's next CEO. |
globenewswire.com |
2025-02-26 08:00:00 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Enovis, Omnicell and Phreesia |
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article. |
zacks.com |
2025-01-24 04:51:10 |
Czytaj oryginał (ang.) |
| 3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects |
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave. |
zacks.com |
2025-01-23 14:21:13 |
Czytaj oryginał (ang.) |
| Enovis™ Announces Leadership Change to International Surgical Business |
Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. |
globenewswire.com |
2025-01-17 08:00:00 |
Czytaj oryginał (ang.) |
| Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600 |
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE: ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE: ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE: CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. |
prnewswire.com |
2025-01-07 20:19:00 |
Czytaj oryginał (ang.) |
| Enovis to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
Wilmington, DE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 43nd Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 13th, 2025, at 9:45 a.m. PST (12:45 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company's website (www.enovis.com) at Events and Presentations. |
globenewswire.com |
2025-01-06 18:15:00 |
Czytaj oryginał (ang.) |
| Enovis Corporation: Reasonably Valued With Caveats |
Medical device concern Enovis Corporation's Q3 results were released on November 6th, showing positive financial performance and future growth prospects. Analysts, including Wells Fargo and Needham, reiterated Buy ratings post earnings with price targets ranging from $62 to $75 per share. The company's growth is benefiting from a recent acquisition, and the stock appears reasonably valued with some caveats. |
seekingalpha.com |
2024-11-22 14:17:13 |
Czytaj oryginał (ang.) |
| Enovis to Participate in Upcoming Investor Conferences |
Wilmington, DE, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: |
globenewswire.com |
2024-11-18 18:10:00 |
Czytaj oryginał (ang.) |
| Enovis (ENOV) Upgraded to Buy: Here's Why |
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-08 15:01:23 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 38.95% Upside in Enovis (ENOV): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-08 12:55:25 |
Czytaj oryginał (ang.) |
| Enovis Corporation (ENOV) Q3 2024 Earnings Call Transcript |
Enovis Corporation (NYSE:ENOV ) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Xuyang Li - Jefferies Jeff Johnson - Baird Brandon Vazquez - William Blair Caitlin Cronin - Canaccord Danielle Antalffy - UBS Mike Matson - Needham & Company Operator Good day, and welcome to the Enovis Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. |
seekingalpha.com |
2024-11-06 14:50:38 |
Czytaj oryginał (ang.) |
| Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates |
Enovis (ENOV) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.56 per share a year ago. |
zacks.com |
2024-11-06 10:16:16 |
Czytaj oryginał (ang.) |
| Enovis Announces Third Quarter 2024 Results |
Wilmington, DE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended September 27, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. |
globenewswire.com |
2024-11-06 08:00:00 |
Czytaj oryginał (ang.) |
| Enovis to Host Third Quarter 2024 Results Conference Call on November 6th |
Wilmington, DE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its third quarter 2024 financial results on Wednesday, November 6th, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. |
globenewswire.com |
2024-10-10 11:00:00 |
Czytaj oryginał (ang.) |
| Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says |
JMP Securities initiated coverage on Enovis Corporation ENOV, a medical technology company focusing on orthopedics. |
benzinga.com |
2024-10-03 19:39:08 |
Czytaj oryginał (ang.) |
| Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies |
WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. |
globenewswire.com |
2024-09-09 19:50:00 |
Czytaj oryginał (ang.) |
| Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene |
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes. |
zacks.com |
2024-08-20 16:56:05 |
Czytaj oryginał (ang.) |
| Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures |
First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. |
globenewswire.com |
2024-08-20 12:00:00 |
Czytaj oryginał (ang.) |
| Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability |
Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert |
globenewswire.com |
2024-08-19 12:00:00 |
Czytaj oryginał (ang.) |
| Enovis to Participate in Upcoming Investor Conferences |
Wilmington, DE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: |
globenewswire.com |
2024-08-12 20:10:00 |
Czytaj oryginał (ang.) |
| Enovis (ENOV) Q2 Earnings Top Estimates |
Enovis (ENOV) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.61 per share a year ago. |
zacks.com |
2024-08-07 12:16:09 |
Czytaj oryginał (ang.) |
| Enovis Announces Second Quarter 2024 Results |
Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET. |
globenewswire.com |
2024-08-07 10:00:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for |
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-31 15:06:19 |
Czytaj oryginał (ang.) |
| Enovis Announces Time Change for Second Quarter 2024 Results Conference Call |
Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on August 7, 2024, but will now be held at 8:00 a.m. Eastern Time, instead of the previously announced time. There is no change to the date, the dial-in or webcasting information. A presentation related to the call will be available on ir.enovis.com. |
globenewswire.com |
2024-07-25 10:00:00 |
Czytaj oryginał (ang.) |
| Enovis to Host Second Quarter 2024 Results Conference Call on August 7th |
Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com. |
globenewswire.com |
2024-07-16 11:00:00 |
Czytaj oryginał (ang.) |
| Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis |
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates. |
zacks.com |
2024-07-15 15:26:08 |
Czytaj oryginał (ang.) |